BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Switches to Frozen Immunotherapy Formula to Boost Potency and Facilitate Transport
The company has announced an increase in the potency of its lead immunotherapy candidate, Bria-IMT, through cryopreservation The frozen formula simplifies logistics and makes it possible for the immunotherapy to reach patients across long distances without a compromise in the safety or efficiency of the treatment The same cryopreservation approach will be utilized in the case of Bria-OTS, BriaCell’s off-the-shelf personalized immunotherapy for advanced breast cancer The use of a novel Bria-IMT frozen formulation is one of the exciting new developments that BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) announced recently. Bria-IMT is the company’s lead immunotherapy candidate. It is…